Exposure to oral bisphosphonates and risk of esophageal cancer.
about
Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studiesEvaluating the impact of database heterogeneity on observational study resultsInterpreting observational studies: why empirical calibration is needed to correct p-valuesEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal womenBisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studiesBisphosphonate drug holiday: choosing appropriate candidatesEpidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this diseaseBisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis.The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summaryOral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from KoreaThe effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data.Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapyBisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans.Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT projectSafety of drugs used in the treatment of osteoporosis.Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosisAdverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.An evaluation of the use of oral bisphosphonates and risk of esophageal cancer.Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies.Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD).A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort studyExposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data.Use of bisphosphonates and reduced risk of colorectal cancer.Clinical utility of denosumab for treatment of bone loss in men and womenLong-term safety concerns of antiresorptive therapy.Can the risk of secondary cancer induction after breast conserving therapy be reduced using intraoperative radiotherapy (IORT) with low-energy x-rays?Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.Combination of Micronutrients for Bone (COMB) Study: bone density after micronutrient intervention.Oral Bisphosphonate and Risk of Esophageal Cancer: A Nationwide Claim Study.Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medicationsExposure to bisphosphonates and risk of cancer: a protocol for nested case-control studies using the QResearch primary care database.Oral bisphosphonates and upper gastrointestinal toxicity: a study of cancer and early signals of esophageal injuryPharmacovigilanceOral Bisphosphonate Exposure and the Risk of Upper Gastrointestinal Cancers.Clinical role of bisphosphonate therapy.Exposure to oral bisphosphonates and risk of cancer.
P2860
Q24288975-6F13E6B5-7984-4BBD-B969-4B2D095C6C59Q24289210-B5F449E9-4D01-4D11-8533-049AFB010FB1Q24289521-F3E15131-92C7-43D9-8368-F167B7D22F79Q24612411-5874687D-D0AE-4F19-B829-9C7C269560EAQ24621774-56F068BC-74E1-455A-94C3-02AD45B39CFBQ27004682-3702CF7A-CC65-4DFC-81F3-E5DC43155F9AQ27027061-4B24191F-BC2A-4B62-A22A-9B6385417307Q27693291-229B263B-2BB6-48CE-9D25-528CCD82BDF8Q28087279-5480597B-B884-4775-A1F4-40CBFEF92A41Q28295416-31AF9247-9925-4FEF-A98C-CF81CF31ACB8Q31052317-FC2717D2-0810-40B3-8352-300DFF753E54Q31156585-6A513628-5FC9-4A14-9EAD-E5E7586EF7B3Q33568586-828D9789-C0A2-4D70-BB68-CB4762F8AAB2Q33715141-0F0C8301-8F40-4500-B7A7-7B169F7D12D5Q33716678-C1F35A0A-CCA3-4B3D-AAD2-123FF87B6072Q33818302-582D7384-89F9-43A6-8385-C000A168A659Q33851671-8A997EBE-A354-4528-AC13-DD2904B6665AQ33949479-B2B95FAF-B97D-434A-92F4-1E3D753D6874Q34104102-FCE6EE95-7DC7-4056-B073-23DFE72817A5Q34158441-BD805C67-130C-4D21-A8F4-1EFB6A6139A9Q34189582-2A4299F9-54C8-43E9-9631-30BB74A3CD1EQ34254269-7E23497A-BDED-4CF9-BC41-C1C903CC6613Q34305113-B0DDA325-B7D4-4698-9058-BBF9A1A7AA95Q34462218-B2045DFA-C479-4E8F-A2EE-AC2844F50450Q34541581-CF689806-C255-4178-8D87-1B4836BB881CQ34550590-EF243D04-7672-467C-AE3B-79EF9DD87373Q34877539-23ABF208-772D-4A4F-B4EA-A28E305B910EQ35092799-29ED2059-3633-4976-BE19-C13AF340B5BAQ35570961-22FE5089-869C-4BB6-AD0A-88B75A8F4160Q35677383-A095A86A-56F2-48DC-92B3-ABC4F7EF7A0BQ35678676-7D496E73-4049-4EB3-8854-C1F9313B47C9Q35691705-060C85B3-EE60-443A-BF5E-69AA6FC6BF1CQ35739607-D56E279B-B071-4F2D-B5AE-CD7FAB11D28DQ35740351-19338A7C-4063-42FE-8FA0-E988AB1498A1Q35753917-FDA21D37-2355-429C-912F-84651649F2BBQ35878736-15F6FC2B-F3B7-40A6-8F94-D6F1208BC9B1Q36081511-B79E7F44-5DB6-4F9F-A7C1-D6BA659C9141Q36132106-3FDCC31A-FCB8-490B-9710-3FCC61853E38Q36311593-D12407C4-8577-493F-9119-1BCBFCD3957AQ36455050-D7CB1836-4FBA-4857-9BBB-196904FFDC32
P2860
Exposure to oral bisphosphonates and risk of esophageal cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Exposure to oral bisphosphonates and risk of esophageal cancer.
@ast
Exposure to oral bisphosphonates and risk of esophageal cancer.
@en
type
label
Exposure to oral bisphosphonates and risk of esophageal cancer.
@ast
Exposure to oral bisphosphonates and risk of esophageal cancer.
@en
prefLabel
Exposure to oral bisphosphonates and risk of esophageal cancer.
@ast
Exposure to oral bisphosphonates and risk of esophageal cancer.
@en
P2860
P356
P1476
Exposure to oral bisphosphonates and risk of esophageal cancer
@en
P2093
Liam J Murray
Marie M Cantwell
P2860
P304
P356
10.1001/JAMA.2010.1098
P407
P577
2010-08-01T00:00:00Z